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Abstract 
Background: Thyroid hormones profoundly influence the cardiovascular system, but 
the effects of mild thyroid dysfunction on the clinical outcome of acute coronary 
syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are not 
well defined. This study aimed to determine the effect of mild thyroid dysfunction on 
12-month prognosis in ACS patients undergoing PCI.  
Methods: In this prospective cohort study with a 12-month follow-up, 1560 individuals 
were divided into four groups based on thyroid hormone levels upon admission: 
euthyroidism (used as a reference group), subclinical hypothyroidism, subclinical 
hyperthyroidism, and low triiodothyronine syndrome (low T3 syndrome). The outcomes 
measured were all-cause mortality, cardiac mortality, nonfatal reinfarction, and 
unplanned repeat revascularization.  
Results: In this study, the prevalence of mild thyroid dysfunction was 10.8%. 
Multivariate analysis showed that low T3 syndrome, but not subclinical hypothyroidism 
or subclinical hyperthyroidism, was associated with a higher rate of all-cause (HR 2.553, 
95% CI 1.093–5.964, p = 0.030) and cardiac mortality (HR 2.594, 95% CI 1.026–6.559, 
p = 0.034), compared with the euthyroidism group. 
Conclusions: Mild thyroid dysfunction was frequent in patients with ACS undergoing 
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PCI. Low T3 syndrome was the predominant feature and was associated with 12-month 
adverse outcomes in these patients. 
Key words: mild thyroid dysfunction, clinical outcome, acute coronary syndrome, 
percutaneous coronary intervention 
 
 
Introduction 
Patients with acute coronary syndrome (ACS) frequently have a poor prognosis, and 
ACS is a major health and economic burden [1–4]. Although the use of percutaneous 
coronary intervention (PCI) and new antiplatelet drugs have greatly improved the 
prognosis [5], patients with ACS still suffer high rates of mortality (up to 5%) and heart 
failure (up to 20%) [6]. Thyroid hormones act on multiple systems within the body, and 
the cardiovascular system is the foremost target [7]. The cardiovascular system may be 
adversely affected even if thyroid hormone levels only change slightly [7]. In patients 
with ACS, a decrease in serum triiodothyronine (T3), as well as the impaired conversion 
of thyroxine (T4) into T3, have been reported [8, 9]. Thyroid hormone related indicators 
are also predictors for thrombus burden [10], severity of coronary artery lesions [11, 12], 
cardiac function [13, 14] and myocardial injury size [8, 9, 15] in ACS patients. However, 
the screening and treatment of mild thyroid dysfunction is still controversial [16–20] 
and not recommended for ACS patients [1–4]. However, mild thyroid dysfunction, 
including subclinical hypothyroidism, subclinical hyperthyroidism, and euthyroid sick 
syndrome (ESS), is frequently present in patients with ACS [21–23]. Additionally, mild 
thyroid dysfunction can also be predicative of an increased risk of mortality in 
heterogeneous patients with various cardiac diseases [21]. However, few studies have 
focused on the association between mild thyroid dysfunction and adverse prognoses in 
patients with coronary heart disease [22, 23]. In this study, the aim was to assess the 
prevalence of mild thyroid dysfunction and the association of mild thyroid dysfunction 
with 12-month prognosis in ACS patients undergoing PCI. 
 
Methods 
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Study design and setting 
This study was based on a prospective cohort, the P-PUSH study, which has been 
previously described [24]. In brief, from January 1, 2015 to July 31, 2016, 1768 patients 
with ACS were hospitalized and underwent PCI at a large hospital in Northeast China 
(Shengjing Hospital of China Medical University, Shenyang, China). Clinical and 
procedural data were obtained by the investigators using electronic medical records, 
interventional imaging data (Picture Archiving and Communications Systems [PACS] 
technology), and operation records. GRACE scores were determined as defined 
previously [1–4]. Prospective clinical follow-up after discharge was performed regularly 
in all cases by direct hospital visits and telephone interviews with the patient’s general 
practitioner/cardiologist, the patient, or the patient’s family. All events were adjudicated 
and classified by two cardiologists. The exclusion criteria of this study were as follows: 
1) primary hypothyroidism or hyperthyroidism (36 cases); 2) concomitant treatment 
with synthetic thyroid hormones, antithyroid drugs, corticosteroids, dopamine, 
dobutamine, or amiodarone (19 cases); 3) loss of follow-up (68 cases); 4) no thyroid 
data (20 cases); and 5) atypical thyroid status (65 cases), including high T4 syndrome 
(12 cases), low T3-low T4 syndrome (20 cases), and other abnormalities (33 cases). 
1560 patients were ultimately included in this study (Fig. 1). This study complies with 
the Declaration of Helsinki, and the Shengjing Hospital of China Medical University 
Research Ethics Committee which approved the research protocol. Written informed 
consent was formally obtained from all participants. 
 
Participants and procedures 
Acute coronary syndrome was classified according to current guidelines [1–4]. 
Briefly, unstable angina is deﬁned as chest discomfort or anginal equivalent, 
ST-segment depression, transitory ST-segment elevation or prominent T-wave inversion, 
and negative cardiac biomarkers (CK-MB, T/I troponin). Non-ST-segment elevation 
myocardial infarction (MI) is deﬁned as chest discomfort or anginal equivalent, 
ST-segment depression, transitory ST-segment elevation or prominent T-wave inversion, 
and positive cardiac biomarkers (CK-MB, T/I troponin). ST-segment elevation MI is 
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defined as chest pain and significant ST-segment elevation (≥ 0.1 mV in at least two 
standard leads or ≥ 0.2 mV in at least two contiguous precordial leads) or new left 
bundle branch block. PCI was performed in accordance with current guidelines, with 
aspiration thrombectomy and glycoprotein IIb/IIIa inhibitor administration performed at 
the discretion of the operators [1–4]. The operators also prescribed periprocedural and 
postprocedural anti-platelet regimens and other cardiovascular medications according to 
the guidelines [1–4]. 
 
Thyroid hormone sampling 
In all cases, venous blood samples were drawn upon admission in standard tubes at 
room temperature, rapidly centrifuged and measured for thyroid-stimulating hormone 
(TSH), free T3 (fT3) and free T4 (fT4) by a completely automated immunoassay 
analyzer (i2000, Abbott, USA) in the core laboratory of Shengjing Hospital. The 
reference intervals for the laboratory were as follows: TSH: 0.3–4.8 uIu/mL; fT3: 
2.63–5.71 pmol/L; fT4: 9.01–19.05 pmol/L. Based on thyroid hormone values, patients 
were categorized into four groups: (1) euthyroidism, with all circulating levels of TSH, 
fT3, and fT4 in the reference range; (2) subclinical hypothyroidism (SHypo), with TSH 
levels between 4.8 and 10 uIu/mL and fT3 and fT4 in the reference range; (3) 
subclinical hyperthyroidism (SHyper), with TSH levels less than 0.3 mIU/L and fT3 and 
fT4 in the reference range; and (4) low T3 syndrome, with fT3 levels less than 2.63 
mIU/L and TSH and fT4 levels in the reference range [7]. 
 
Clinical endpoints 
The clinical endpoints of this study were all-cause mortality, cardiac mortality, 
nonfatal reinfarction, and unplanned repeat revascularization, including any unplanned 
repeat PCI or surgical bypass of target or non-target vessels. All endpoints are defined 
by the standardized definitions [25]. 
 
Data availability 
All data generated or analyzed during this study are included in this published article 
5 
and its supplementary information files (Appendix). 
 
Statistical analysis 
Quantitative variables with normal distribution are represented as mean ± standard 
deviation (SD) and compared by variance analysis. Quantitative variables without 
normal distribution are represented as median (interquartile range [IQR]) and compared 
with a Kruskal-Wallis H test. Categorical variables are presented as counts and 
proportions (%) and were compared with the χ2 test. Cox proportional hazards 
regression modeling by forward stepwise procedure was used to analyze the effect of 
variables on event-free survival. The euthyroidism group was considered the reference 
group. Variables included in the model were chosen by separate univariate analyses 
(Appendix S1 and S2); those with p value of < 0.05 were included in the final model 
(Table 3). Age, gender, current smoking, prior heart failure (HF), heart rate on 
admission, left ventricular ejection fraction (LVEF), MI on admission, creatinine, left 
main coronary artery disease, number of stents, drug-eluting stent, and angiotensin 
converting enzyme inhibitor/angiotensin receptor blockers (ACEI/ARBs) were included 
in the Cox regression multivariable analysis of all-cause mortality (Appendix S1). Age, 
gender, prior HF, heart rate on admission, LVEF, MI on admission, creatinine, left main 
coronary artery disease, drug-eluting stent and ACEI/ARBs were included in the Cox 
regression multivariable analysis of cardiac mortality (Appendix S2). Results were 
reported as hazard ratios (HRs) with associated 95% confidence intervals (CIs). The 
cumulative event rate was estimated from Kaplan-Meier curves and compared using the 
log-rank test. All tests were two-sided, and statistical significance was defined as p < 
0.05. All statistical analyses were performed with SPSS version 19 (SPSS Inc., Chicago, 
Illinois, USA). 
 
Results 
Participants and baseline characteristics 
Figure 1 represents the flowchart for patient selection. The final study cohort 
included 1560 ACS patients undergoing PCI, including 169 patients with mild thyroid 
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dysfunction (10.8%), and were divided into four groups: 1) euthyroidism group, 1391 
(89.2%) patients; 2) SHypo group, 49 (3.1%) patients; 3) SHyper group, 57 (3.7%) 
patients; and 4) low T3 syndrome group, 63 (4.0%) patients. Clinical characteristics are 
shown in Table 1. The SHypo and low T3 syndrome groups had significantly higher 
percentages of females (51.0% and 49.2%, respectively) compared to the euthyroidism 
(27.7%) and SHyper (21.1%) groups. The low T3 syndrome group had a tendency 
towards older age and higher troponin-I levels on admission and lower LVEF and rate 
of statin use at discharge. The percentage of prior HF, MI on admission, cardiogenic 
shock and left main coronary artery disease were also significantly higher in the low T3 
syndrome group. Individuals in the SHyper group were more likely to have 
dyslipidemia. There was a significant trend of lower systolic blood pressure upon 
admission in SHyper group (Table 1). 
 
Clinical endpoints by thyroid status 
The clinical endpoints are shown in Table 2. During the 12-month follow-up period, 
there was a significant trend of higher all-cause mortality and cardiac mortality in the 
low T3 syndrome group. 
The cumulative event curves for all-cause mortality can be seen in Figure 2. Log-rank 
tests indicated significant differences among the four groups (p = 0.001). Furthermore, 
as shown in Table 3, a significantly increased risk of all-cause mortality was found in 
the low T3 syndrome group, but not in the SHypo or SHyper groups, compared with the 
euthyroidism group (HR 3.496, 95% CI 1.579–7.729, p = 0.002). After adjusting for 
covariates, the low T3 syndrome group still displayed a significantly higher all-cause 
mortality, compared with the euthyroidism group (HR 2.553, 95% CI 1.093–5.964, p = 
0.030) (Table 3). 
Using Kaplan-Meier analysis (Fig. 3), it was found that there were significant 
differences in cardiac mortality among the four groups (p < 0.001). Univariate analysis 
also revealed that the low T3 syndrome group, but not the SHypo or SHyper groups, 
had a higher rate of cardiac mortality, compared with the euthyroidism group (HR 3.781, 
95% CI 1.596–8.959, p = 0.003) (Table 3). This was confirmed again by Cox regression 
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multivariable analysis (HR 2.594, 95% CI 1.026–6.559, p = 0.034) (Table 3). There 
were no significant differences in nonfatal reinfarction or unplanned repeat 
revascularization among the four groups (Table 3).  
 
Discussion 
The present study examined the association between mild thyroid dysfunction and 
12-month prognosis in ACS patients undergoing PCI, and demonstrated that: 1) the 
prevalence of mild thyroid dysfunction was as high as 10.8% in patients with ACS 
undergoing PCI; 2) low T3 syndrome, but not subclinical hypothyroidism or subclinical 
hyperthyroidism, was associated with a higher rate of all-cause and cardiac mortality; 
and 3) there was no association between mild thyroid dysfunction and nonfatal 
reinfarction or unplanned repeat revascularization in ACS patients undergoing PCI. 
Mild thyroid dysfunction is frequently present in patients with various cardiac 
diseases [21]. Further, plasma thyroid hormone levels may also change in ACS patients 
[8, 9]. Iervasi et al. [22] found that the prevalence of thyroid dysfunction was up to 40% 
in cardiac patients undergoing coronary angiography. Another study showed a 15% 
prevalence of mild thyroid dysfunction in patients with ST-elevation MI (STEMI) who 
underwent PCI [23]. In this study, there was a 10.8% prevalence of mild thyroid 
dysfunction in patients with ACS undergoing PCI. However, the current guidelines do 
not recommend the routine assessment of thyroid function in ACS patients [1–4]. The 
prevalence of mild thyroid dysfunction in the present study was far lower than that 
reported by Iervasi et al. [22]. This is mainly due to differing definitions of thyroid 
dysfunction. Iervasi et al. [22] used a broader scope of definition: euthyroid patients 
with normal values of TSH, fT3, and fT4; low T3 syndrome patients with fT3 < 2.0 
pg/mL; hypothyroid patients with TSH > 3.8 uIU/mL; and hyperthyroid patients with 
TSH < 0.3 uIU/mL. 
Thyroid hormones extensively affect the physiological and pathological processes 
of the cardiovascular system [7] and are associated with coronary atherosclerosis [11, 
12], thrombus burden [10], cardiomyocyte injury [8, 9, 15], and cardiac function 
recovery [13, 14]. For the first time, in a total of 573 consecutive heterogeneous cardiac 
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patients undergoing thyroid function evaluation, Iervasi et al. [21] reported that 
subclinical hypothyroidism and subclinical hyperthyroidism were associated with an 
increased risk of cardiac mortality. In contrast, patients with STEMI undergoing PCI, 
had no significant differences in adverse prognoses between subclinical hypothyroidism 
or subclinical hyperthyroidism and euthyroidism [23]. In addition, the present study 
found that neither subclinical hypothyroidism or subclinical hyperthyroidism were 
associated with a higher rate of all-cause or cardiac mortality, nor were they associated 
with a higher rate of nonfatal reinfarction or unplanned repeat revascularization in ACS 
patients undergoing PCI. The reason for different conclusions may be that the latter two 
studies only included ischemic heart disease patients undergoing PCI, but not 
heterogeneous patients with various cardiac diseases. Also, PCI could greatly improve 
the prognosis of ischemic heart disease [1–4]. 
Low T3 syndrome was found to be a strong prognostic predictor of death in 
patients with cardiac disease [21, 26–28]. It then was verified by other research that low 
T3 syndrome was associated with adverse outcomes in patients after experiencing ACS 
[29]. However, only 27.7% patients in that study received PCI, which can greatly 
improve the prognosis of ischemic heart disease and is now widely available for ACS 
patients [1–4]. For the first time, we studied the association between low T3 syndrome 
and the prognosis of ACS patients undergoing PCI. The present study found that low T3 
syndrome was associated with a higher rate of all-cause and cardiac mortality in ACS 
patients undergoing PCI. Mechanistic correlates of these findings have been 
demonstrated. T3, which is the most important bioactive thyroid hormone for 
cardiomyocytes, is mostly produced by a process of deiodination of T4 [7]. It can affect 
cardiomyocytes via genomic and nongenomic actions [7]. T3 regulates transcription by 
binding hormone receptors (TRs) in the nucleus, which then bind to thyroid hormone 
response elements (TREs) present in regulatory regions of target genes. Nongenomic 
actions of T3 include thyroid hormone signaling, changes in thyroid hormone levels, 
and changes in thyroid hormone receptors. Previous studies have confirmed that the 
thyroid hormone receptor TRα1 can limit myocardial injury and post-ischemic cardiac 
remodeling through T3 binding, and it regulates genes related to contractile proteins, 
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pacemaker activity and conduction, cell growth, differentiation and metabolism [30–32]. 
Also, thyroid hormones could affect cardiac apoptosis through the suppression of 
ischemia reperfusion-induced activation of the pro-apoptotic p38 mitogen-activated 
protein kinase (MAPK) and upregulation of cardio-protective molecules such as heat 
shock protein 27 (HSP27) and heat shock protein 70 (HSP70), which are also involved 
in ischemic preconditioning [30–32]. T3 may also regulate plasma membrane ion 
currents, activate survival pathways, and decrease oxidative stress in mitochondria [7]. 
Therefore, heart rate, cardiac contractility, vascular smooth muscle, and endothelial 
function will be modulated [7]. When T3 is low, negative effects on the cardiovascular 
system, such as delayed diastolic filling, decreased cardiac contractility, and increased 
vascular resistance will occur [7]. Thyroid hormones also indirectly effect myocytes by 
activating the inflammatory immune response through genomic and nongenomic 
mechanisms [33]. Clinical studies also confirmed that low T3 was associated with larger 
thrombus burden [10], higher severity of coronary artery lesions [11, 12], worse cardiac 
function [13, 14] and larger myocardial injury size [8, 9, 15] in ACS patients. 
Taken together, in ACS patients, decreased levels of T3 have a severe pathological 
effect, rather than acting as an adaptive response to minimize catabolism [34]. 
Considering the results of this study and the others mentioned, it is worthwhile to 
monitor thyroid hormone levels in patients with ACS. Doing so will help to identify 
patients at high risk of adverse events and mortality. Also, of interest is the potential of 
thyroid hormones as a therapeutic target for improving the prognosis of ACS since 
patients still suffer adverse outcomes [6]. In fact, experimental evidence from animal 
models has shown that T3 therapy could limit infarct extension, protect against 
reperfusion injury, improve cardiac structure and function, decrease the incidence of 
tachyarrhythmias, and reduce adverse left ventricular remodeling [7]. Furthermore, a 
previous study found that thyroid replacement therapy was beneficial in preventing 
coronary disease progression and other cardiovascular events in patients with 
hypothyroidism undergoing PCI [35]. However, the efficacy and safety of T3 therapy 
has not yet been confirmed in randomized, controlled clinical trials in patients with ACS 
and low T3 syndrome undergoing PCI. Moreover, there are still several problems 
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related to thyroid hormone replacement, such as the type of thyroid hormone used (T3 
or T4), medication route (parenteral or oral), the timing related to onset of ACS, the 
duration of medication use, and complications associated with overtreatment, including 
atrial fibrillation and bone fracture. Adequately powered randomized studies need to be 
performed to obtain meaningful conclusions before thyroid hormone replacement can 
become a routine clinical treatment for ACS patients, such as the ThyrAMI trial (Trial 
registration: ISRCTN; trial number: ISRCTN52505169) and the TRUST trial (Specific 
Program Cooperation — Theme Health, Proposal No: 278148-2, NCT01660126) [36, 
37]. 
This study had several limitations. First, this study was prospective and observational, 
so potential confounders and selection bias could not be completely eliminated. Second, 
when patients suffer from ACS, the secretion of thyroid hormone will fluctuate in the 
early phase of the disease [7]. Particularly, the level of T3 will drop in the first 2–3 days 
after the ischemic event. However, in this study, thyroid function tests were only 
performed at admission and not repeated later, as recommended by the guidelines 
[16–19]. Thus, transient forms of thyroid dysfunction could be excluded and low T3 
syndrome was likely underestimated. Third, studies have indicated that iodinated 
contrast media may influence thyroid function [22, 38, 39]. In this study, the thyroid 
function of some patients was tested after the use of iodinated contrast media because 
they needed emergency PCI. Finally, the raw number of events in this study was quite 
small during the follow-up period, which may be a limitation in the overall 
interpretation of the study results. 
 
Conclusions 
Mild thyroid dysfunction was frequent in patients with ACS undergoing PCI, and low 
T3 syndrome was the predominant feature. Low T3 syndrome, but not subclinical 
hypothyroidism or subclinical hyperthyroidism, was associated with a higher rate of 
all-cause and cardiac mortality. 
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Figure 1. Flow diagram of participant selection. 
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Figure 2. Kaplan-Meier cumulative event curves for all-cause mortality by thyroid 
status. 
 
 
 
Figure 3. Kaplan-Meier cumulative event curves for cardiac mortality by thyroid status. 
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Table 1. Baseline patient characteristics. 
Variable All (n = 1560) 
Euthyroidism (n 
= 1391) 
Subclinical 
hypothyroidism 
(n = 49) 
Subclinical 
hyperthyroidism 
(n = 57) 
Low T3 
(n = 63) 
P 
Clinical characteristics       
Age 61.8 ± 11.1 61.5 ± 11.1 63.9 ± 9.5 62.3 ± 13.3 65.6 ± 9.7* 0.018 
Female 453 (29.0%) 385 (27.7%) 25 (51.0%) 12 (21.1%) 31 (49.2%)* < 0.001 
Diabetes mellitus 486 (31.2%) 417 (30.0%) 19 (38.8%) 23 (40.4%) 27 (31.2%) 0.057 
Hypertension 905 (58.0%) 801 (57.6%) 31 (63.3%) 30 (52.6%) 43 (68.3%) 0.256 
Dyslipidemia 1121 (71.9%) 1016 (73.0%) 30 (61.2%) 34 (59.6%) 41 (65.1%) * 0.025 
Current smoking 711 (45.6%) 640 (46.0%) 16 (32.7%) 29 (50.9%) 26 (41.3%) 0.210 
History of MI 169 (10.8%) 146 (10.5%) 6 (12.2%) 9 (15.8%) 8 (12.7%) 0.585 
Prior PCI 149 (9.6%) 131 (9.4%) 6 (12.2%) 7 (12.3%) 5 (7.9%) 0.772 
Prior HF 74 (4.7%) 59 (4.2%) 4 (8.2%) 4 (7.0%) 7 (11.1%) * 0.039 
MI on admission 1055 (67.7%) 918 (66.0%) 29 (59.2%) 51 (89.5%) 57 (90.5%) * < 0.001 
Cardiogenic shock 18 (1.2%) 10 (0.7%) 1 (2.0%) 2 (3.5%) 5 (7.9%) < 0.001 
SBP on admission [mmHg] 136.1 ± 22.7 136.7 ± 22.6 138.3 ± 22.3 127.7 ± 23.5 129.3 ± 23.4* 0.001 
HR on admission [bpm] 75.4 ± 14.3 75.2 ± 14.1 74.3 ± 10.6 77.4 ± 14.7 77.9 ± 18.6 0.510 
LVEF [%] 58.3 ± 8.7 58.5 ± 8.6 60.5 ± 8.0 55.9 ± 10.2 55.7 ± 8.5 0.002 
Laboratory characteristics 
Creatinine [µmol/L], 
median (Q1, Q3) 
71 (61, 85） 71 (61, 84) 70 (62, 94) 66 (58, 88) 75 (58, 113) 0.358 
Troponin-I on admission 
[ng/mL], median (Q1, Q3) 
0.67 (0.01, 
21.00) 
0.65 (0.01, 
18.18) 
0.27 (0.01, 12.02) 
16.00 (0.67, 
82.00) 
25.20 (2.10, 66.60) * < 0.001 
TSH [µIU/mL], median 
(Q1, Q3) 
1.41 (0.83, 2.26) 1.41 (0.88, 2.16) 6.00 (5.23, 6.82) 0.22 (0.13, 0.27) 1.40 (0.61, 2.37) < 0.001 
fT3 [pmol/L], median (Q1, 
Q3) 
3.93 (3.47, 4.34) 3.95 (3.55, 4.36) 4.04 (3.41, 4.41) 3.97 (3.37, 4.34) 2.36 (2.05, 2.52) < 0.001 
fT4 [pmol/L], median (Q1, 12.92 (11.77, 12.98 (11.82, 12.14 (10.79, 13.49 (12.33, 12.32 (10.54, 13.74) < 0.001 
18 
Q3) 14.29) 14.32) 13.08) 15.14) 
PCI characteristics       
Left main disease 145 (9.3%) 119 (8.6%) 8 (16.3%) 7 (12.3%) 11 (17.5%) * 0.025 
Three-vessel disease 369 (23.7%) 331 (23.8%) 9 (18.4%) 14 (24.6%) 15 (23.8%) 0.849 
Number of stents, median 
(Q1, Q3) 
2 (1, 2) 2 (1, 2) 2 (1, 2) 1 (1, 2) 2 (1, 2) 0.910 
Drug-eluting stent 1504 (96.4%) 1342 (96.5%) 47 (95.9%) 53 (93.0%) 62 (98.4%) 0.437 
Medications at discharge       
ASA 1550 (99.4%) 1383 (99.4%) 49 (100.0%) 57 (100.0%) 61 (96.8%) 0.068 
Clopidogrel 1417 (90.8%) 1266 (91.0%) 44 (89.8%) 52 (91.2%) 55 (87.3%) 0.784 
Ticagrelor 119 (7.6%) 103 (7.4%) 5 (10.2%) 4 (7.0%) 7 (11.1%) 0.643 
Statin 1534 (98.3%) 1373 (98.7%) 49 (100.0%) 54 (94.7%) 58 (92.1%) < 0.001 
ACEI/ARBs 808 (51.8%) 734 (52.8%) 19 (38.8%) 29 (50.9%) 26 (41.3%) 0.083 
Beta-blockers 782 (50.1%) 705 (50.7%) 17 (34.7%) 32 (56.1%) 28 (44.4%) 0.091 
ASA — acetylsalicylic acid; ACEI/ARBs — angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers; HF — heart failure; HR — heart rate; LVEF — left ventricular ejection fraction; MI 
— myocardial infarction; PCI — percutaneous coronary intervention; SBP — systolic blood pressure 
 
 
Table 2. Frequency of clinical outcomes by thyroid status. 
 
 
 
All (n = 
1560) 
Euthyroidis
m (n = 1391) 
Subclinical 
hypothyroidis
m (n = 49) 
Subclinical 
hyperthyroidis
m (n = 57) 
Low T3 
(n =63) 
P 
All-cause mortality 59 (3.8%) 47 (3.4%) 1 (2.0%) 4 (7.0%) 7 (11.1%) 0.007 
cardiac mortality 48 (3.1%) 37 (2.7%) 1 (2.0%) 4 (7.0%) 6 (9.5%) 0.005 
Nonfatal reinfarction 22 (1.4%) 18 (1.3%) 1 (2.0%) 1 (1.8%) 2 (3.2%) 0.629 
Unplanned repeat 
revascularization 
60 (3.8%) 50 (3.6%) 4 (8.2%) 5 (8.8%) 1 (1.6%) 0.062 
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Table 3. Hazard ratios for all-cause and cardiac mortality by thyroid status. 
 
Univariate analysis Multivariate analysisa 
Hazard ratio 
(95% CI) 
P 
Hazard ratio 
(95% CI) 
P 
All-cause mortality     
Euthyroidism 1 [Reference]  1 [Reference] a  
Subclinical hypothyroidism 
0.603 
(0.083–4.367) 
0.616 
0.557 
(0.077–4.043) 
0.563 
Subclinical hyperthyroidism 
2.165 
(0.780–6.009) 
0.138 
1.970 
(0.706–5.494) 
0.195 
Low T3 
3.493 
(1.579–7.729) 
0.002 
2.553 
(1.093–5.964) 
0.030 
Cardiac mortality     
Euthyroidism 1 [Reference]  1 [Reference] b  
Subclinical hypothyroidism 
0.767 
(0.105–5.589) 
0.793 
0.696 
(0.095–5.087) 
0.721 
Subclinical hyperthyroidism 
2.749 
(0.980–7.714) 
0.055 
2.431 
(0.860–6.874) 
0.094 
Low T3 
3.781 
(1.596–8.959) 
0.003 
2.594 
(1.026–6.559) 
0.034 
Nonfatal reinfarction     
Euthyroidism 1 [Reference]    
Subclinical hypothyroidism 
1.589 
(0.212–11.900) 
0.652   
Subclinical hyperthyroidism 
1.368 
(0.183–10.244) 
0.761   
Low T3 
2.478 
(0.575–10.681) 
0.223   
Unplanned repeat revascularization 
Euthyroidism 1 [Reference]    
Subclinical hypothyroidism 
2.342 
(0.846–6.485) 
0.101   
Subclinical hyperthyroidism 
2.047 
(0.739–5.668) 
0.168   
Low T3 
0.435 
(0.060–3.147) 
0.409   
aAdjusted for age, gender, current smoking, prior HF, heart rate on admission, LVEF, 
myocardial infarction on admission, cardiogenic shock, creatinine, left main disease, 
number of stents, drug-eluting stent, and ACEI/ARBs 
bAdjusted for age, gender, prior HF, heart rate on admission, LVEF, myocardial 
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infarction on admission, cardiogenic shock, creatinine, left main disease, drug-eluting 
stent, and ACEI/ARBs 
Abbreviations — see Table 1 
 
 
Appendix S1 Effects of multiple variables on all-cause mortality in Univariate Analysis. 
 HR 95% CI P 
Age 1.064 1.039-1.091 ＜0.001 
Gender 1.257 0.733-2.154 0.406 
Diabetes Mellitus 1.049 0.608-1.812 0.863 
Hypertension 1.655 0.951-2.880 0.075 
Dyslipidemia 0.819 0.474-1.414 0.474 
Current smoking 1.776 1.029-3.066 0.039 
History of MI 1.297 0.615-2.733 0.494 
Prior PCI 0.160 0.022-1.156 0.069 
Prior HF 4.228 2.141-8.346 ＜0.001 
SBP on admission, mm Hg 0.994 0.982-1.005 0.294 
Heart rate on admission, beats/min 1.036 1.024-1.047 ＜0.001 
LVEF, % 0.951 0.927-0.974 ＜0.001 
Myocardial infarction on admission 1.728 1.313-2.273 ＜0.001 
Cardiogenic shock 9.476 3.790-23.696 ＜0.001 
Creatinine (umol/L) 1.001 1.000-1.002 0.010 
Troponin-I on admission, ng/mL 1.003 0.995-1.011 0.472 
Left main disease 2.314 1.202-4.455 0.012 
Three-vessel disease 1.321 0.752-2.320 0.333 
Number of stents 0.760 0.586-0.985 0.036 
Drug-eluting stent 0.508 0.342-0.753 0.001 
Aspirin 20.284 0.000-556.19 0.667 
Clopidogrel 1.099 0.440-2.747 0.840 
Ticagrelor 1.115 0.446-2.787 0.816 
Statin 20.610 0.003-982.11 0.502 
ACEI/ ARBs 0.467 0.272-0.800 0.006 
Beta-blockers 0.672 0.400-1.130 0.134 
MI, myocardial infarction; bpm, beats per minute; LVEF, left ventricular ejection fraction; h, hour 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix S2 Effects of multiple variables on cardiac mortality in Univariate Analysis. 
 HR 95% CI P 
Age 1.062 1.034-1.091 ＜0.001 
Gender 1.006 0.540-1.874 0.985 
Diabetes Mellitus 1.327 0.740-2.380 0.343 
Hypertension 1.451 0.796-2.643 0.224 
Dyslipidemia 0.947 0.508-1.764 0.863 
Current smoking 1.401 0.781-2.512 0.259 
History of MI 1.412 0.633-3.147 0.399 
Prior PCI 0.198 0.027-1.438 0.109 
Prior HF 3.475 1.559-7.747 0.002 
SBP on admission, mm Hg 0.993 0.981-1.006 0.311 
Heart rate on admission, beats/min 1.036 1.023-1.049 ＜0.001 
LVEF, % 0.945 0.920-0.971 ＜0.001 
Myocardial infarction on admission 1.673 1.243-2.251 0.001 
Cardiogenic shock 11.793 4.669-29.785 ＜0.001 
Creatinine (umol/L) 1.001 1.000-1.002 0.015 
Troponin-I on admission, ng/mL 1.004 0.995-1.012 0.387 
Left main disease 2.999 1.530-5.879 0.001 
Three-vessel disease 1.483 0.805-2.730 0.206 
Number of stents 0.812 0.617-1.068 0.136 
Drug-eluting stent 0.452 0.303-0.675 ＜0.001 
Aspirin 20.284 0.000-1407.1 0.708 
Clopidogrel 1.532 0.476-4.929 0.475 
Ticagrelor 0.799 0.248-2.570 0.706 
Statin 20.608 0.001-1856.47 0.545 
ACEI/ ARBs 0.456 0.250-0.832 0.010 
Beta-blockers 0.701 0.395-1.244 0.225 
MI, myocardial infarction; bpm, beats per minute; LVEF, left ventricular ejection fraction; h, hour 
 
 
 
 
 
 
 
